Barclays analyst Andrew Mok raised the firm’s price target on Tenet Healthcare (THC) to $190 from $171 and keeps an Overweight rating on the shares. While 2024 was a “particularly great” year for hospitals, 2025 is also attractive and there is earnings upside for both HCA and Tenet with reasonable organic growth assumptions, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on THC:
- Tenet Healthcare price target raised to $205 from $195 at Wells Fargo
- Tenet Healthcare price target raised to $190 from $180 at Truist
- Tenet Healthcare price target raised to $177 from $168 at Cantor Fitzgerald
- Tenet Healthcare price target raised to $217 from $197 at UBS
- Tenet Healthcare price target raised to $183 from $174 at RBC Capital